Fig. 7. Combined treatment with trametinib and anti-PD1 in immunocompetent mice transplanted with syngeneic PDACs.

(A) Schematic representation of the experimental workflow. The transplanted PDAC cell line was obtained from KPC mice (KRasG12D/+, Trp53172H/+, p48-Cre). Trametinib treatment was administered by oral gavage, while the anti-mouse PD1 antibody was administered intraperitoneally. (B) Body weight in mice assigned to the four experimental groups was determined at the end of the treatment. (C) Survival curves of transplanted C57/BL6 mice in the different treatment groups. Significance was assessed using log-rank (Mantel-Cox) test and indicated as follows: ****P < 0.0001. n = 3 mice in the combined treatment group were still alive at the time of the analysis.